Unveiling
triple-negative breast cancer

Lifting the curtain on an often overlooked disease

"We have been researching breast cancer for many years now, and triple-negative is the most difficult-to-treat and aggressive form with no standard of care. The tumour is complex, but we are committed to finding advances in this area."

Dr. Nana Scotto
Franchise Head, Breast Cancer and Gynaecologic Malignancies, Roche

Triple-negative breast cancer is the rarest form of breast cancer, yet still accounts for 15-20% of cases.1 This form of breast cancer differs from others through: the underlying tumour biology, the type of people most at risk of developing the disease, and the experiences they have during diagnosis and treatment.

By lacking the three main characteristics associated with breast cancer cells, triple-negative breast cancer represents a critical clinical challenge, and people diagnosed with the disease can be made to feel like there is little hope to combat the disease.

“For anyone receiving a breast cancer diagnosis, the news is bad. And for someone diagnosed with triple-negative breast cancer, there aren’t just as many options for treatment with other types of breast cancer.”

Concepción Biurrún Martínez
Spanish Federation of Patients with Breast Cancer (FECMA)

Women with triple-negative breast cancer are less likely to survive the first five years after diagnosis compared to those with other forms of breast cancer.2 With limited treatment options and a poorer prognosis, it is essential to continue advancing research in triple-negative breast cancer.

“It is so important to continue research, we are looking into new ways of personalising our approach, focusing on the role of the immune system to identify and destroy cancer cells and targets that could bring new ways of improving patient care in the future. We are aiming to bring new hope for people with triple-negative breast cancer with our science-driven approach and we are doing so by working in collaboration with the medical community and patient groups.”

Dr. Nana Scotto
Franchise Head, Breast Cancer and Gynaecologic Malignancies, Roche

Roche has a long heritage of working in breast cancer, and continues to be committed to advancing research in triple-negative breast cancer to improve outcomes for people with this complex disease. With research and development we are looking towards a future where people with triple-negative breast cancer may have as many options as those with other types of breast cancer.

“I believe there is hope, because 10-15 years ago breast cancer took the lives of so many women and, with early diagnosis and new treatment options, survival has improved greatly. It’s now the time for triple-negative breast cancer, and there is hope for a solution.”

Concepción Biurrún Martínez
Spanish Federation of Patients with Breast Cancer (FECMA)

References

1) Yao H et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–1924

2) Li X et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. 2016;161(2):279-287.

Tags: Patients, Oncology